Abstract: Histone deacetylase inhibitors (HDACi) can induce hyperacetylation of both histone and non-histone target resulting in epigenetic reprogramming and altered activity, stability and localisation of non-histone proteins to ultimately mediate diverse biological effects on cancer cells and their microenvironment. Clinical trials have demonstrated single agent HDACi to have activity in hematological malignancies, in particular T-cell lymphoma and Hodgkin lymphoma. Combination strategies with standard therapies based on pre-clinical data are being employed with significant success due to their excellent side effect profile. Correlative studies will provide valuable information on the sub-groups of patients more likely to respond or be resistant to HDACi therapy, while long-term monitoring for toxicities is also needed.
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Export to BibTeX
MDPI and ACS Style
Bishton, M.J.; Johnstone, R.W.; Dickinson, M.; Harrison, S.; Prince, H.M. Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. Pharmaceuticals 2010, 3, 2674-2688.
Bishton MJ, Johnstone RW, Dickinson M, Harrison S, Prince HM. Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. Pharmaceuticals. 2010; 3(8):2674-2688.
Bishton, Mark J.; Johnstone, Ricky W.; Dickinson, Michael; Harrison, Simon; Prince, H. Miles. 2010. "Overview of Histone Deacetylase Inhibitors in Haematological Malignancies." Pharmaceuticals 3, no. 8: 2674-2688.